STOCK TITAN
  1. Home
  2. News
  3. AVXL

Anavex Life Sciences - AVXL STOCK NEWS

Welcome to our dedicated page for Anavex Life Sciences news (Ticker: AVXL), a resource for investors and traders seeking the latest updates and insights on Anavex Life Sciences stock.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for neurodegenerative and neurodevelopmental disorders. Headquartered in New York, Anavex focuses on precision medicine to treat diseases with high unmet medical needs, such as Alzheimer's disease, Parkinson's disease, Rett syndrome, and schizophrenia.

Anavex's lead compound, ANAVEX 2-73 (blarcamesine), is an orally available small molecule targeting sigma-1 and muscarinic receptors. It aims to restore cellular homeostasis, showing promise in multiple CNS disorders. Blarcamesine has successfully completed Phase 2a and Phase 2b/3 trials for Alzheimer's disease and various studies in Rett syndrome, including a recent Phase 2/3 EXCELLENCE pediatric trial demonstrating significant improvements in Rett Syndrome Behaviour Questionnaire (RSBQ) scores.

The company also has other promising drug candidates, such as ANAVEX 3-71, targeting sigma-1 and M1 muscarinic receptors. This candidate has exhibited disease-modifying activity in Alzheimer's disease models and is currently in a Phase 2 trial for schizophrenia.

Anavex actively engages in partnerships and collaborations, including support from the Michael J. Fox Foundation for Parkinson's Research. With a robust intellectual property portfolio, Anavex is committed to advancing its pipeline through rigorous clinical trials to bring effective treatments to market.

Recent highlights include presenting at key industry conferences and filing a Marketing Authorisation application with the European Medicines Agency (EMA) for blarcamesine in Alzheimer's disease. Anavex also recently bolstered its executive team with seasoned professionals to drive its R&D and clinical strategies forward.

For more information, visit www.anavex.com or follow the company on Twitter, Facebook, Instagram, and LinkedIn.

News

Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference

Rhea-AI Summary
Anavex Life Sciences Corp. announces participation in the 44th Annual TD Cowen Health Care Conference. Christopher U Missling, PhD, President & Chief Executive Officer, will present the Company's developments in neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease and Parkinson's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences
-
News

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

Rhea-AI Summary
Anavex Life Sciences Corp. reported financial results for its fiscal quarter ended December 31, 2023, and provided updates on its key pipeline including blarcamesine for Alzheimer's disease and other CNS diseases. The company also announced various business highlights and financial data, including cash and cash equivalents of $143.8 million at December 31, 2023, and a net loss of $8.6 million for the first quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
earnings
-
News

Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024

Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) will release its financial results for the fiscal quarter ended December 31, 2023, on February 7, 2024. The company will host a conference call to review the financial results and provide an update on its growth strategy. Anavex is a clinical-stage biopharmaceutical company focusing on therapeutics for neurodegenerative and neurodevelopmental disorders. The webcast and conference call information are available on Anavex's website and can be accessed by dialing a phone number for participants in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
earnings
News

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans

Rhea-AI Summary
Anavex Life Sciences Corp. announced the findings from the ANAVEX®3-71 first-in-human study, which achieved its safety objectives. The study demonstrated that ANAVEX®3-71 is linear, dose proportional, and time invariant at single ascending doses of 5 to 200 mg, with no effect from food. The publication further supports ANAVEX®3-71's drug development program, showcasing its potential to treat cognitive and behavioral deficits in neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
News

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Rhea-AI Summary
Anavex Life Sciences Corp. announces the initiation of a placebo-controlled Phase 2 trial of ANAVEX®3-71 for the treatment of schizophrenia, which is expected to begin in Q2 2024. ANAVEX®3-71 is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects, offering the potential to treat all symptom domains of schizophrenia without the side effects of standard antipsychotics. The trial will study positive, negative, and cognitive domains of schizophrenia based on ANAVEX®3-71’s ability to synergistically activate both SIGMAR1 and M1 muscarinic receptors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
clinical trial
-
News

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) has been granted a new U.S. Patent expanding the coverage of ANAVEX®2-73 (blarcamesine) therapy to address a range of symptoms exhibited by patients suffering from neurodevelopmental and neurological conditions related to MeCP2 gene mutations. The patent is expected to remain in force until at least January 2037, further reinforcing the company's position in providing novel and effective therapies for debilitating neurodevelopmental and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.15%
Tags
none
News

Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) announces participation in the 42nd Annual J.P. Morgan Healthcare Conference. President and CEO, Christopher U Missling, PhD, to present on January 11, 2024, at 10:30am PST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.02%
Tags
conferences
-
News

Anavex Life Sciences Provides an Update on Rett Syndrome Program

Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) announced topline results from the Phase 2/3 EXCELLENCE clinical study in pediatric Rett Syndrome. The study evaluated the clinical efficacy, safety, and tolerability of 30 mg ANAVEX®2-73 in 92 pediatric patients. The study showed improvement in the Rett Syndrome Behaviour Questionnaire (RSBQ) but did not meet the Clinical Global Impression – Improvement scale (CGI-I). Anavex believes a high placebo response may have masked the therapeutic effect of the drug. A preliminary review of the safety results indicates no new safety signals in the study. Over 91% of patients completing the trial continued into a 48-week open-label extension study (OLE), which is ongoing. The company has established Compassionate Use Programs in Canada, Australia, and the UK for pediatric patients. ANAVEX®2-73 has previously received Fast Track designation, Rare Pediatric Disease designation, and Orphan Drug designation from the FDA for the treatment of Rett syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.07%
Tags
none
-
News

Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome

Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) announced the first entire clinical gene pathway data from the ANAVEX®2-73-RS-002 AVATAR Rett syndrome trial. The study confirmed that Rett syndrome is a neurodevelopmental disorder with a key metabolic component, addressable with therapeutic intervention. The ANAVEX®2-73 treatment showed significant activation of key developmental and metabolic gene pathways, potentially compensating for dysregulated genes. The study included 33 patients with Rett syndrome and analyzed gene expression changes, single nucleotide polymorphisms/variants, and transcriptomics analysis. The results highlighted significant differences between the active treatment group and placebo, suggesting potential correction of metabolic alterations in patients with Rett syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.06%
Tags
none
News

Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease

Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has deemed oral blarcamesine for Alzheimer’s disease eligible for submission of a Union Marketing Authorisation in the EU under the centralised procedure. Anavex aims to submit the Marketing Authorisation Application in 2024. Blarcamesine addresses a broader Alzheimer’s disease population compared to monoclonal antibodies and has shown significant improvement in dementia symptoms and reduction of pathological aggregation of amyloid in early Alzheimer’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.2%
Tags
none

FAQ

What is the current stock price of Anavex Life Sciences (AVXL)?

The current stock price of Anavex Life Sciences (AVXL) is $8.63 as of December 20, 2024.

What is the market cap of Anavex Life Sciences (AVXL)?

The market cap of Anavex Life Sciences (AVXL) is approximately 711.4M.

What is Anavex Life Sciences Corp's primary focus?

Anavex Life Sciences Corp focuses on developing novel therapeutics for neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and schizophrenia.

What is ANAVEX 2-73?

ANAVEX 2-73 (blarcamesine) is Anavex's lead drug candidate. It targets sigma-1 and muscarinic receptors to restore cellular homeostasis and has shown promise in treating various CNS disorders.

What recent results were obtained from Anavex's trials?

Recent trials for ANAVEX 2-73 in Rett syndrome showed significant improvements in Rett Syndrome Behaviour Questionnaire (RSBQ) scores. The company is also progressing in trials for Alzheimer's disease and schizophrenia with ANAVEX 3-71.

What partnerships does Anavex Life Sciences have?

Anavex partners with several organizations, including the Michael J. Fox Foundation for Parkinson's Research, which supports the development of ANAVEX 2-73 for Parkinson's disease.

What are Anavex's recent business highlights?

Recent highlights include presenting at key industry conferences, filing a Marketing Authorisation application with the European Medicines Agency (EMA) for blarcamesine in Alzheimer's disease, and strengthening the executive team.

Where is Anavex Life Sciences headquartered?

Anavex Life Sciences is headquartered in New York, USA.

How can I stay updated on Anavex Life Sciences' developments?

You can stay updated by visiting their website at www.anavex.com and following their social media profiles on Twitter, Facebook, Instagram, and LinkedIn.

What is the significance of ANAVEX 3-71?

ANAVEX 3-71 targets sigma-1 and M1 muscarinic receptors, showing disease-modifying activity in Alzheimer's disease models. It is currently in a Phase 2 trial for schizophrenia.

What makes Anavex Life Sciences' approach unique?

Anavex uses precision medicine to develop therapeutics based on genomic data, aiming to address high unmet medical needs in CNS disorders.

Who are the recent additions to Anavex's executive team?

Recent additions include Dr. Juan Carlos Lopez-Talavera as Senior VP of Research and Development, Dr. Terrie Kellmeyer as Senior VP of Clinical Development, and Dr. Jeffrey Edwards as VP of Clinical Pharmacology and Science.

Stock AVXL logo
Anavex Life Sciences

Nasdaq:AVXL

AVXL Rankings

#2811 Ranked by Market Cap
N/A Ranked by Dividends

AVXL Stock Data

711.43M
82.21M
3.05%
32.08%
22.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK